Quebec Public Health Institute

Québec, Canada

Quebec Public Health Institute

Québec, Canada

Time filter

Source Type

Sauvageau C.,Quebec Public Health Institute | Sauvageau C.,Laval University | Dufour-Turbis C.,Laval University
Human Vaccines and Immunotherapeutics | Year: 2016

ABSTRACT: Diseases associated with the human papilloma virus (HPV) are particularly common among men who have sex with men (MSM). Unlike heterosexual men, MSM do not benefit from the herd protection provided by the vaccination of girls. In this review, we synthesize the available evidence on HPV vaccination for MSM. We also present the recommendations of the Québec Immunization Committee (CIQ) in this regard, which are: to provide targeted vaccination for MSM up to 26 years of age and in-school vaccination of preadolescent boys since this is the best approach to take to have a real impact on the burden related to HPV in the MSM population and to provide direct protection for all men. © 2016 Taylor & Francis.


Malenfant S.,Laval University | Goulet C.,Laval University | Nadeau L.,Laval University | Hamel D.,Quebec Public Health Institute | Emery C.A.,University of Calgary
Journal of Science and Medicine in Sport | Year: 2012

Objectives: To determine if a difference exists between the incidence and intensity of the physical contacts of Pee Wee (aged 11-12 years) ice hockey players according to whether the players participate in a league in which body checking is permitted (Calgary, Canada) compared to a league in which body checking is not permitted (Québec City, Canada). Design: Cohort study conducted in Québec City and Calgary during the 2007-2008 Pee Wee ice hockey season. Methods: Ten games were randomly selected for each city (. n=. 20) and analysed. Games were videotaped and subsequently analysed with a validated observation system allowing quantification of the intensity of the various physical contacts. Incidence rate ratios (RR) based on multivariate Poisson regression were used to compare the physical contacts between provinces. All analyses were controlling for game period, score difference, and zone on the playing surface. Results: A total of 2418 physical contacts with the trunk and 757 other physical contacts were observed. Very light intensity trunk physical contacts were more frequent in Québec City (adjusted incidence RR [ARR]: 0.68; 95% CI: 0.48-0.97). Very high intensity trunk physical contacts were more frequent in Calgary (ARR: 12.72; 95% CI: 4.48-36.14). Hooking (ARR: 0.89; 95% CI: 0.84-0.95) and slashing (ARR: 0.91; 95% CI: 0.85-0.97) were more frequent in Québec City. Conclusions: Results suggest that players' behaviours are different in leagues where body checking is permitted compared to leagues where it is not permitted. Policy allowing body checking in Pee Wee ice hockey increases the frequency and intensity of physical contacts. © 2012 Sports Medicine Australia.


Robitaille N.,CHU Sainte Justine | Delage G.,Hema Quebec | Long A.,Hema Quebec | Thibault L.,Hema Quebec | Robillard P.,Quebec Public Health Institute
Vox Sanguinis | Year: 2010

Background and Objectives IgA deficiency is common (1/500) and up to 40% of affected individuals will develop anti-IgA. A few studies suggested that passive transfusion of anti-IgA was not associated with an increased risk of allergic reactions. This study was designed to assess the safety of transfusing blood components containing anti-IgA. Materials and Methods IgA-deficient blood donors with and without anti-IgA were identified from Héma- Québec's (HQ) computerized database. IgA deficiency was confirmed by an ELISA method and the presence of anti-IgA by a passive hemagglutination assay. Blood donations from IgA-deficient donors issued to hospitals between March 1999 and December 2004 were retrieved. Medical charts of recipients were reviewed for the occurrence of a suspected transfusion reaction. Presence and nature of transfusion reactions were assessed blindly by an adjudicating committee. Results A total of 323 IgA-deficient blood products were issued by HQ to 55 hospitals. Of these, 48 agreed to participate [315 blood products (97·5%)]. A total of 272 products were transfused: 174 contained anti-IgA, and 98 did not. Only two minor allergic reactions occurred in each group. Incidence of allergic reactions was 1·15% in the anti-IgA group and 2·04% in the group without anti-IgA (P = 0·91). There was no anaphylactic reaction in either group. Conclusions This study indicates that the proportion of allergic reactions does not appear to be greater in recipients of blood components containing anti-IgA compared to recipients of non-anti-IgA-containing components. Allowing donations from IgA-deficient donors with anti-IgA may therefore be contemplated. © 2010 International Society of Blood Transfusion.


Goulet C.,Laval University | Roy T.-O.,Laval University | Nadeau L.,Laval University | Hamel D.,Quebec Public Health Institute | And 2 more authors.
International Journal of Environmental Research and Public Health | Year: 2016

Background: Ice hockey has one of the highest sport participation and injury rates in youth in Canada. Body checking (BC) is the predominant mechanism of injury in leagues in which it is permitted. The objectives of this study were to determine whether the incidence and types of physical contact differ for Bantam players (aged 13–14 years) who were exposed to BC at Pee Wee level (aged 11–12 years) in Calgary, Alberta versus Bantam players who were not exposed to BC at Pee Wee level in Québec City, Québec. All teams were exposed to BC at bantam level; Methods: A cohort study was conducted in Québec City and Calgary. Sixteen games for Calgary and 15 for Québec City were randomly selected and analysed with a validated observation system to quantify five intensities of physical contact and to observe different types of physical contact such as slashing and holding; Results: A total of 5610 incidences of physical contact with the trunk and 3429 other types of physical contact were observed. Very light intensity trunk contact was more frequent in Calgary (adjusted incidence RR (ARR): 1.71; 95% CI: 1.28–2.29). Holding (ARR: 1.04; 95% CI: 1.02–1.07) and slashing (ARR: 1.38; 95% CI: 1.07–1.77) were more frequent in Calgary; Conclusion: Results suggest that players’ physical contacts differ between Bantam leagues in which BC was permitted at Pee Wee level and leagues in which it was not permitted until Bantam level. © 2016 by the authors; licensee MDPI, Basel, Switzerland.


Gilca V.,Quebec Public Health Institute | Gilca V.,Laval University | De Serres G.,Quebec Public Health Institute | De Serres G.,Laval University | And 13 more authors.
Vaccine | Year: 2011

Background: In 2009, several countries used the ASO3-adjuvanted pandemic A/H1N1 vaccine. We assessed the persistence of antibody and the priming induced by a single paediatric dose of this vaccine in children. Methods: Children aged 15-120 months vaccinated one year before with the ASO3-adjuvanted monovalent pandemic vaccine were tested for the presence of antibody against 2010-2011 TIV components (A/California/7/2009(H1N1), A/Wisconsin/15/2009 (H3N2 A/Perth/16/2009-like) and B/Brisbane/60/2008) before and 21-28 days after each dose of 2010-2011 TIV. Hemagglutinationinhibition (HAI) assay was used. Children received one or two doses of 2010-2011 TIV at 21-28 days interval in relation with their previous immunization status. Results: The results of 128 children were included in the ATP analysis. Before the 2010-2011 TIV administration, 46% of children showed sero-protection to the A/California/7/2009(H1N1) strain (HAI titre ≥40) with lower rates of sero-protection to the H3N2A/Perth/16/2009 (37%) and B/Brisbane/60/2008 (19%). After the first dose of 2010-2011 TIV, 98%, 75%, and 57% of vaccinees attained a sero-protective titre to A/California/7/2009(H1N1), A/Perth/16/2009(H3N2), and B/Brisbane/60/2008 strain, respectively. The youngest age group showed significantly lower antibody response to the influenza B component compared to the older age groups after the first dose of vaccine. Among vaccinees who received the second dose of TIV, 96% and 87% had a sero-protective titre to H3N2A/Perth/16/2009 and B/Brisbane/60/2008, respectively. The 2010-2011 TIV was well tolerated. Conclusions: We found substantial persistence of antibody to the A/California/7/2009 strain one year after a single paediatric dose of AS03-adjuvanted pandemic vaccine and a seroprotective level of antibody to this strain in virtually all children who received one year later a single dose of the 2010-2011 TIV. In contrast, two doses of the 2010-2011 TIV were necessary to induce an adequate immune response to the A/Perth/16/2009(H3N2) and B/Brisbane/60/2008 strains in children previously naïve to seasonal vaccine. © 2011 Elsevier Ltd.


Goulet C.,Laval University | Hagel B.E.,University of Calgary | Hamel D.,Quebec Public Health Institute | Legare G.,University of Quebec at Rimouski
Journal of Science and Medicine in Sport | Year: 2010

There is evidence to suggest that the rate of injury is lower for expert skiers and snowboarders than for beginners. A better understanding of the relation between injury severity and skill level is also needed for planning injury prevention strategies. Our objective was to examine the severity and location of injuries sustained by self-reported expert and beginner skiers and snowboarders. A case-control study design was used. Injured skiers and snowboarders had to report their skill level on a 5 point scale (1: "beginner"; 5: "expert"). Two sets of severely injured cases were defined based on the type of injury and ambulance evacuation. Controls were those who did not sustain severe injuries. Logistic regression analyses were performed to relate injury severity to skill level. Subjects were 22 078 injured skiers and snowboarders who reported to the ski patrol with an injury sustained on the slopes of an alpine ski centre of the Canadian province of Québec during the seasons 2001-2002 to 2004-2005. Compared with beginners, experts had an increased risk of suffering from a severe injury (adjusted odds ratio [AOR]: 1.88; 95% CI: 1.58-2.23). Expert snowboarders were also more likely to suffer from a severe injury or be evacuated by ambulance (AOR: 1.18; 95% CI: 1.02-1.38). Results suggest that the type of activities or manoeuvres performed by expert skiers and snowboarders may increase the risk of sustaining a severe injury compared with beginner participants. © 2008 Sports Medicine Australia.


Gilca V.,Quebec Public Health Institute | Gilca V.,Laval University | Gilca V.,University of Québec | Sauvageau C.,Quebec Public Health Institute | And 17 more authors.
Human Vaccines and Immunotherapeutics | Year: 2014

Background. No immunogenicity data has been reported after a single dose of the quadrivalent HPV vaccine (qHPV-Gardasil®) and no data are available on co-administration of this vaccine with the HAV/HBV vaccine (Twinrix-Junior®). Two pre-licensure studies reported similar anti-HPV but lower anti-HBs titers when co-administering HPV and HBV vaccines. Objectives. To assess the immunogenicity of the qHPV and HAV/HBV vaccine when co-administered (Group-Co-adm) or given one month apart (Group-Sep) and to measure the persistence of HPV antibodies three years post-second dose of qHPV vaccine in both study groups. Methods. 416 9-10 year-old girls were enrolled. Vaccination schedule was 0-6 months. Anti-HAV and anti-HBs were measured in all subjects 6 months post-first dose and 1 month post-second dose. Anti-HPV were measured 6 months post-first dose in Group-Co-adm and in all subjects 1 and 36 months post-second dose. Results. Six months post-first dose: 100% of subjects had detectable anti-HAV and 56% and 73% had detectable anti- HBs in Group-Co-Adm and Group-Sep, respectively. In Group-Co-adm 94, 100, 99 and 96% had detectable antibodies to HPV 6, 11, 16 and 18, respectively. One month post-second dose of qHPV and HAV/HBV vaccine, in both study groups 99.5-100% of subjects had an anti-HAV titer ≥ 20IU/L, 97.5-97.6% an anti-HBs level ≥ 10IU/L, and 100% had an anti-HPV titer ≥ 3LU. Thirty-six months post-second dose of qHPV all but four subjects (99%) had antibodies to HPV18 and 100% had antibodies to HPV6, 11 and 16. The great majority (97-100%) had an anti-HPV titer ≥ 3 LU. Post-second dose administration of qHPV and HAV/HBV, no meaningful difference was observed in the immune response in the two study groups to any component of vaccines. Conclusions. The results indicate that qHPV and HAV/HBV can be given during the same vaccination session. Two doses of of qHPV and HAV/HBV vaccines induce a strong immune response. Three years post-second dose of qHPV, the great majority of subjects had antibodies to HPV types included in the vaccine. A two-dose schedule for pre-adolescents might be a reasonable alternative to the currently approved three-dose schedules. © 2014 Landes Bioscience.


In 2009, several countries used the ASO3-adjuvanted pandemic A/H1N1 vaccine. We assessed the persistence of antibody and the priming induced by a single paediatric dose of this vaccine in children.Children aged 15-120 months vaccinated one year before with the ASO3-adjuvanted monovalent pandemic vaccine were tested for the presence of antibody against 2010-2011 TIV components (A/California/7/2009(H1N1), A/Wisconsin/15/2009 (H3N2 A/Perth/16/2009-like) and B/Brisbane/60/2008) before and 21-28 days after each dose of 2010-2011 TIV. Hemagglutination-inhibition (HAI) assay was used. Children received one or two doses of 2010-2011 TIV at 21-28 days interval in relation with their previous immunization status.The results of 128 children were included in the ATP analysis. Before the 2010-2011 TIV administration, 46% of children showed sero-protection to the A/California/7/2009(H1N1) strain (HAI titre 40) with lower rates of sero-protection to the H3N2A/Perth/16/2009 (37%) and B/Brisbane/60/2008 (19%). After the first dose of 2010-2011 TIV, 98%, 75%, and 57% of vaccinees attained a sero-protective titre to A/California/7/2009(H1N1), A/Perth/16/2009(H3N2), and B/Brisbane/60/2008 strain, respectively. The youngest age group showed significantly lower antibody response to the influenza B component compared to the older age groups after the first dose of vaccine. Among vaccinees who received the second dose of TIV, 96% and 87% had a sero-protective titre to H3N2A/Perth/16/2009 and B/Brisbane/60/2008, respectively. The 2010-2011 TIV was well tolerated.We found substantial persistence of antibody to the A/California/7/2009 strain one year after a single paediatric dose of AS03-adjuvanted pandemic vaccine and a seroprotective level of antibody to this strain in virtually all children who received one year later a single dose of the 2010-2011 TIV. In contrast, two doses of the 2010-2011 TIV were necessary to induce an adequate immune response to the A/Perth/16/2009(H3N2) and B/Brisbane/60/2008 strains in children previously nave to seasonal vaccine.

Loading Quebec Public Health Institute collaborators
Loading Quebec Public Health Institute collaborators